# NATCOPHARM (NATCOPHARM) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/natcopharm

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹812.3
- Change: -0.73%
- As of: 2026-09-18
- 1D return: -0.59%
- 5D return: -0.64%
- 1M return: -7.30%
- Latest complete quarter: fy27_q1

## Faxioms Analysis

_As of 2026-09-18_

### Technical Outlook

As of September 18, 2026, NATCOPHARM's technical stance is predominantly bearish across multiple timeframes. Daily, weekly, and monthly trends are all indicated as bearish, with the price trading below key moving averages like the 20-day, 50-day, and 200-day Simple Moving Averages (SMAs) and Exponential Moving Averages (EMAs) on the daily chart. This alignment suggests a consistent downward pressure. The stock is currently positioned near its nearest support level of ₹809.33, which is approximately 0.5% below the current price of ₹813.4. The nearest resistance is observed at ₹814.67, a pivot level about 0.16% above the current price. Recent market activity includes one downside event in the last 30 days, and a notable downward gap occurred on September 16, 2026, with a return of -1%. The stock's current drawdown stands at -42%, with annualized volatility at 40% and an Average True Range (ATR) of 2.58% of the price, indicating elevated risk.

Key watch conditions include monitoring the price action around the ₹814.67 resistance level. A sustained move above this level could signal a potential shift. Conversely, a break below the ₹809.33 support could reinforce the bearish trend. The presence of multiple bearish signals across daily, weekly, and monthly charts suggests that any upward movements may face significant headwinds unless these indicators show a clear reversal.

- The stock's current price is ₹813.4 as of September 18, 2026.
- Daily, weekly, and monthly trends are all aligned in a bearish direction.
- Nearest support is at ₹809.33 (approx. 0.5% below current price).
- Nearest resistance is at ₹814.67 (approx. 0.16% above current price).
- A downward gap occurred on September 16, 2026, with a -1% return.

- Inside Bar
- Doji
- Harami
- Bearish Engulfing Reversal

### What Changed

As of September 18, 2026, NATCO Pharma's stock price has seen a slight decrease, closing at ₹813.4 compared to its previous price of ₹818.25. The available evidence does not indicate any new filings or news developments for the company on this date. The company's profile on the NSE remains unchanged in the provided context.

- On September 18, 2026, NATCO Pharma's closing price was ₹813.4.
- The previous closing price on record was ₹818.25.
- No new filings or news were reported for NATCO Pharma as of September 18, 2026.

### Official Filings

Natco Pharma Limited has announced plans for a significant capital raise through a rights issue, aiming to secure up to ₹1,300 crore. This move, approved by the Board of Directors on September 9, 2026, involves issuing fully paid-up equity shares. A Fund-Raising Committee has been established to manage this process. Concurrently, the company is proceeding with its 43rd Annual General Meeting (AGM) on September 30, 2026. At the AGM, shareholders will vote on adopting the financial statements for the fiscal year ended March 31, 2026, and confirm interim dividends totaling ₹5.00 per share. A key agenda item is the potential authorization for the board to raise up to ₹2,000 crores through various securities, including a Qualified Institutional Placement (QIP). The company also plans to revise its demerger scheme with Natco Crop Health Sciences Limited post-rights issue to maintain the original share swap ratio. In preparation, Natco Pharma submitted its Annual Report for FY 2025-26 on September 4, 2026, detailing its risk management framework.

- On September 9, 2026, the Board approved a rights issue to raise up to ₹1,300 crore.
- A Draft Letter of Offer for the rights issue, aggregating up to ₹13,000 million, was filed on September 9, 2026.
- The 43rd AGM is scheduled for September 30, 2026, to adopt FY 2025-26 financials and confirm ₹5.00 per share in interim dividends.
- Shareholders will consider authorizing the board to raise up to ₹2,000 crores via securities issuance, including a QIP.
- The company filed its Annual Report for FY 2025-26 on September 4, 2026.

- Natco Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on September 09, 2026. |SUBJECT: Outcome of Board Meeting
- Intimation of Draft letter of Offer |SUBJECT: Rights Issue
- Natco Pharma Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication
- Board Meeting Intimation |Meeting Date: 09-Sep-2026
- Fund Raising |Meeting Date: 09-Sep-2026
- NATCO PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 09-Sep-2026 to consider Fund raising. |SUBJECT: Board Meeting Intimation
- Natco Pharma Limited has informed the Exchange about Notice of Shareholders Meeting for Annual General Meeting to be held on 30-Sep-2026 |SUBJECT: Notice Of Shareholders Meetings-XBRL
- Natco Pharma Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 30, 2026 |SUBJECT: Shareholders meeting
- AS ON DATE : 04-SEP-26
- Natco Pharma Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates

### Fundamentals

NATCO Pharma's recent operating performance shows a mixed trend across its reported quarters. Revenue from operations saw an increase from ₹647.30 crore in Q3 FY2025-26 to ₹739.10 crore in Q4 FY2025-26, before a slight decrease to ₹735.20 crore in Q1 FY2026-27. Profit Before Exceptional Items and Tax followed a similar pattern, rising from ₹161.10 crore in Q3 FY2025-26 to ₹144.10 crore in Q4 FY2025-26, and then increasing to ₹185.60 crore in Q1 FY2026-27. The company's Profit Loss For Period also fluctuated, standing at ₹151.30 crore in Q3 FY2025-26, jumping to ₹269 crore in Q4 FY2025-26, and settling at ₹206.50 crore in Q1 FY2026-27. Finance costs have shown a consistent increase over the periods, from ₹9.50 crore in Q3 FY2025-26 to ₹13 crore in Q1 FY2026-27. Other expenses also saw a significant rise from ₹196.10 crore in Q3 FY2025-26 to ₹298.30 crore in Q4 FY2025-26, before decreasing to ₹221.90 crore in Q1 FY2026-27. The company's ability to translate revenue into profit and manage its expense base will be key monitoring areas.

- Revenue from operations was ₹647.30 crore in Q3 FY2025-26, ₹739.10 crore in Q4 FY2025-26, and ₹735.20 crore in Q1 FY2026-27.
- Profit Before Exceptional Items and Tax was ₹161.10 crore in Q3 FY2025-26, ₹144.10 crore in Q4 FY2025-26, and ₹185.60 crore in Q1 FY2026-27.
- Profit Loss For Period was ₹151.30 crore in Q3 FY2025-26, ₹269 crore in Q4 FY2025-26, and ₹206.50 crore in Q1 FY2026-27.
- Finance Costs increased from ₹9.50 crore in Q3 FY2025-26 to ₹13 crore in Q1 FY2026-27.
- Other Expenses were ₹196.10 crore in Q3 FY2025-26, ₹298.30 crore in Q4 FY2025-26, and ₹221.90 crore in Q1 FY2026-27.

### Bull Case

The provided evidence does not contain specific factual data points to support a constructive interpretation of NATCO Pharma's operating performance, financial health, or market setup as of September 18, 2026. While a recent news headline notes general growth in the domestic pharma market driven by price hikes and new launches, it also highlights concerns about weak volumes and US tariff uncertainty, indicating a mixed sector outlook. Technical indicators across daily, weekly, and monthly timeframes show a 'bearish' supertrend direction, and recent period returns are negative, including a year-to-date return of -0.08. Nearest support levels are observed at 809.33 and 808.72, while resistance is noted at 814.67.

- Domestic pharma market sustains growth momentum, but margins remain key

### Bear Case

The company's stock is exhibiting a bearish trend across daily, weekly, and monthly timeframes, as indicated by technical indicators such as the Supertrend direction and declining moving average slopes. Recent performance shows negative returns across multiple periods, including a -8% return year-to-date and a -15% return over the last six months. The stock is trading below its 20, 50, and 200-day simple moving averages, and its current price is below the daily Supertrend level of ₹873.52. Furthermore, the company has experienced a significant drawdown of -42%, with a maximum drawdown of -47%, suggesting considerable volatility and a sustained decline from previous highs.

- The stock's daily Supertrend direction is bearish as of 2026-09-18.
- The company has recorded a year-to-date return of -8% and a 6-month return of -15%.
- The current stock price of ₹813.4 is below its 20-day, 50-day, and 200-day simple moving averages.
- The stock has experienced a current drawdown of -42% and a maximum drawdown of -47%.

- Domestic pharma market sustains growth momentum, but margins remain key

### FAQs

**What is the company's plan for raising capital and its implications?**

On September 9, 2026, Natco Pharma Limited announced a plan to raise up to ₹1,300 crore through a rights issue of equity shares. The company has filed a Draft Letter of Offer for this purpose, aggregating up to ₹13,000 million. The Board of Directors has formed a Fund-Raising Committee to manage this issuance. Additionally, the company intends to revise its demerger scheme between Natco Pharma Limited and Natco Crop Health Sciences Limited after the rights issue is completed, aiming to maintain the original share swap ratio.

**What is the current technical trend and key price levels for NATCOPHARM shares?**

As of September 18, 2026, NATCOPHARM shares are trading below key moving averages, with the daily Supertrend indicator showing a 'bearish' direction at ₹873.52. The 20-day Exponential Moving Average (EMA) is at ₹840.41, and the 50-day EMA is at ₹880.37. Nearest resistance levels are identified at ₹814.67 (pivot) and ₹823.58 (high), while support levels are noted at ₹809.33 (low) and ₹808.72 (low).

**How has NATCOPHARM's stock performed over different periods?**

As of September 18, 2026, NATCOPHARM's stock has experienced negative returns across various timeframes. The year-to-date (YTD) return is -0.08%. Over the past month, the return was -0.09%, and over the last six months, it was -0.15%. The stock has also seen a return of -0.08% over the past year and a cumulative return of -0.42% since its inception.

- Domestic pharma market sustains growth momentum, but margins remain key
- Natco Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on September 09, 2026. |SUBJECT: Outcome of Board Meeting
- Intimation of Draft letter of Offer |SUBJECT: Rights Issue
- Natco Pharma Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication
- Board Meeting Intimation |Meeting Date: 09-Sep-2026
- Fund Raising |Meeting Date: 09-Sep-2026
## Technical analytics

- As of: 2026-09-18
- Daily trend: Strong Downtrend
- Weekly trend: Weak Downtrend
- Pivot point: ₹814.67
- Risk regime: Higher Price Risk

### Support levels
- 808.71875
- 787.6375
- 757.05

### Resistance levels
- 867.465771484375
- 883.8671875
- 918.3875

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | -0.59% |
| return_10 | -2.97% |
| return_1m | -9.46% |
| return_1y | -8.02% |
| return_20 | -7.30% |
| return_3m | -7.93% |
| return_5 | -0.64% |
| return_6m | -15.09% |
| return_since_start | -41.79% |
| return_ytd | -8.42% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | high_risk |
| label | Higher price risk |
| summary | Recent drawdown or price variability is materially high and may lead to larger short-term outcomes. |
| maximum_drawdown | -46.58% |
| annualized_volatility | +40.16% |

## Quarterly financials

- Latest complete quarter: fy27_q1

# Revenue Declines Sharply Year-Over-Year; Profitability Metrics Show Divergent Sequential Movements

Natco Pharma’s Q1 FY2026-27 revenue of ₹735.2 crore was 44.7% lower than the same quarter last year, though nearly flat compared to the previous quarter. Profit before tax increased 28.8% sequentially, but net profit fell 23.2% due to a swing in tax expense from a credit in the prior quarter to an expense this quarter. Other expenses declined significantly, while finance costs rose.

## Revenue

Revenue from operations was ₹735.2 crore in the quarter, essentially unchanged from ₹739.1 crore in Q4 FY2025-26 (a decline of 0.5%). Year-over-year, revenue fell sharply from ₹1,328.9 crore in Q1 FY2025-26, a decline of 44.7%.

The revenue pattern over the last five quarters shows a spike in the first half of FY2025-26 (Q1 and Q2 both above ₹1,300 crore), followed by a drop to the ₹650–740 crore range in the second half and continuing into Q1 FY2026-27. The current quarter’s revenue is in line with the recent two quarters, following a decline from the elevated levels of the prior year.

## Profitability and Tax

Profit before tax (PBT) was ₹185.6 crore, up 28.8% from ₹144.1 crore in Q4 FY2025-26, despite the slight revenue decline. This improvement was aided by a reduction in other expenses. Compared to the same quarter last year, PBT was 67.6% lower, reflecting the much lower revenue base.

Net profit for the period was ₹206.5 crore, down 23.2% from ₹269 crore in Q4 FY2025-26, even though PBT increased. The divergence is explained by a significant swing in tax expense: Q4 FY2025-26 included a tax credit of ₹-89.2 crore, while Q1 FY2026-27 recorded a tax expense of ₹63.4 crore. This ₹152.6 crore swing in the tax line more than offset the PBT increase, causing net profit to fall.

Year-over-year, net profit declined 57.0% from ₹480.3 crore, in line with the PBT decline.

## Expenses and Finance Costs

Other expenses were ₹221.9 crore, down 25.6% sequentially from ₹298.3 crore and down 37.7% from ₹355.9 crore a year ago. The sequential decline in other expenses contributed to the PBT improvement despite flat revenue.

Finance costs rose to ₹13 crore from ₹10.9 crore in the prior quarter (up 19.3%) and from ₹3.2 crore in Q1 FY2025-26 (up 306%).

## Other Comprehensive Income

Other comprehensive income (OCI) was ₹111 crore, up 33.4% from ₹83.2 crore in Q4 FY2025-26 and up 182% from ₹39.3 crore a year ago. OCI includes items such as revaluation gains and foreign currency translation adjustments that are not part of the profit calculation. Including OCI, total comprehensive income (net profit + OCI) was ₹317.5 crore, compared to ₹352.2 crore in Q4 and ₹519.6 crore in Q1 FY2025-26. The increase in OCI partially offset the decline in net profit, but total comprehensive income still fell sequentially and year-over-year.

## Management Commentary

Natco Pharma reported Q1FY27 consolidated revenue of ₹794.4 crore, down from ₹1,390.6 crore in the same quarter last year, primarily due to lower Lenalidomide revenue. The base business, however, showed growth. Net profit declined to ₹206.5 crore from ₹480.3 crore. The company also announced an additional 13.25% stake acquisition in Adcock Ingram Holdings, increasing its total holding to 49%, which is expected to bolster its international presence. Management is evaluating raising up to ₹2,000 crore through various equity instruments to fund future growth initiatives. An interim dividend of ₹1.50 per share has been declared for FY2026-27.

## Key Takeaway

The quarter shows a sharp year-over-year decline in revenue and profit. Sequentially, revenue stabilized, and profit before tax improved as other expenses fell. However, net profit declined due to a swing in the tax line. Finance costs have risen notably. The revenue level is in line with the previous two quarters, following a decline from the elevated levels of the prior year.

### Ratios

## Official filings

- 2026-09-09 — Generic Announcement: Natco Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/NATCOPHARM_09092026115332_BoardOutcome09092026.pdf)
- 2026-09-09 — Generic Announcement: Natco Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/NATCOPHARM_09092026174838_SE_DLOF_Intimation.pdf)
- 2026-09-05 — Generic Announcement: Natco Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/NATCOPHARM_05092026134738_PaperPublications_Letter.pdf)
- 2026-09-04 — Board Meeting Notice: Natco Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_1299_WebXMLFile_20260904_190632505.xml)
- 2026-09-04 — Board Meeting Notice: Natco Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/NATCOPHARM_04092026190501_SE_Intimation04092026.pdf)
- 2026-09-04 — Generic Announcement: Natco Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_1299_WebXMLFile_20260904_190632505.xml)
- 2026-09-04 — Generic Announcement: Natco Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/NOTICE_OF_SHAREHOLDERS_MEETINGS_1299_WebXMLFile_20260904_201624535.xml)
- 2026-09-04 — Generic Announcement: Natco Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/NATCOPHARM_04092026205650_AGM_Notice_SE.pdf)
- 2026-09-03 — Annual Report: Natco Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/annual_reports/AR_31441_NATCOPHARM_2025_2026_A_20000089_04092026200058.pdf)
- 2026-09-02 — Generic Announcement: Natco Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/NATCOPHARM_02092026190918_Investormeet_Intimation_02092026.pdf)
- 2026-09-02 — Generic Announcement: Natco Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1299_WebXMLFile_20260902_191111557.xml)
- 2026-08-26 — Official Filing: NATCO PHARMA LIMITED — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/IT_1299_WebXMLFile_20260826_132233786.xml)
- 2026-08-25 — Press Release: Natco Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/NATCOPHARM_25082026121818_PressRelease_eGenesis_25082026.pdf)
- 2026-08-25 — Generic Announcement: Natco Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/REG30_Restructuring_1299_WebXMLFile_20260825_123423188.xml)
- 2026-08-24 — Generic Announcement: Natco Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/NATCOPHARM_24082026214320_Investormeet_Intimation24082026.pdf)
- 2026-08-21 — Press Release: Natco Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/NATCOPHARM_21082026172327_DisclosuretoSE21082026.pdf)
- 2026-08-19 — Earnings Presentation: Natco Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/NATCOPHARM_19082026090147_InvestorPresentation19082026.pdf)
- 2026-08-19 — Generic Announcement: Natco Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/NATCOPHARM_19082026191553_Investormeet_Intimation19082026.pdf)
- 2026-08-18 — Generic Announcement: Natco Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/NATCOPHARM_18082026123626_Q1EarningscallTranscript.pdf)
- 2026-08-16 — Generic Announcement: Natco Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/NATCOPHARM_16082026195553_Investormeet_Intimation16082026.pdf)
- 2026-08-16 — Generic Announcement: Natco Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/NATCOPHARM_16082026090553_Q1202627PaperPublications.pdf)
- 2026-08-14 — Generic Announcement: Natco Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/NATCOPHARM_14082026141604_Record_date_intimation.pdf)
- 2026-08-14 — Generic Announcement: Natco Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/NATCOPHARM_14082026140905_BMOutcome_14082026.pdf)
- 2026-08-14 — Generic Announcement: Natco Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/NATCOPHARM_14082026173614_IP_14082026.pdf)
- 2026-08-14 — Generic Announcement: Natco Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/NATCOPHARM_14082026185528_Q1EarningscallAudioLink.pdf)

## News and market events

- 2026-09-16 — Mint: **Domestic pharma market sustains growth momentum, but margins remain key** — Domestic pharma growth remained strong in August, led by price hikes and new launches, but weak volumes and US tariff uncertainty mean a sustained margin recovery will be crucial for sector performance. — [Source](https://www.livemint.com/market/mark-to-market/indian-pharma-market-ipm-pharma-stocks-domestic-pharma-dr-reddy-s-laboratories-sun-pharma-ajanta-pharma-glenmark-11789538290089.html)
- 2026-08-25 — The Hindu: **Natco Pharma invests $14mn in biotech firm eGenesis; total investment at $22mn** — Natco Pharma invests $14 million in eGenesis, raising total funding to $22 million for innovative organ transplantation solutions. — [Source](https://www.thehindu.com/business/industry/natco-pharma-invests-14mn-in-biotech-firm-egenesis-total-investment-at-22mn/article71388835.ece)
- 2026-08-24 — BUSINESS: **Stock Alert: Caplin Point Lab, Natco pharma, Federal Bank, B. R. Goyal Infra** — Shares of Steel Authority of India (SAIL) barred from fresh F&O positions on 24 August 2026. — [Source](https://www.business-standard.com/markets/capital-market-news/stock-alert-caplin-point-lab-natco-pharma-federal-bank-b-r-goyal-infra-126082400105_1.html)
- 2026-08-24 — The Hindu: **Symbiotec Pharmalab IPO opens today: Price, dates, lot size and key details** — What brokerage say on the IPO? — [Source](https://www.thehindubusinessline.com/markets/symbiotec-pharmalab-ipo-opens-today-price-dates-lot-size-and-key-details/article71381357.ece)
- 2026-08-24 — Economic Times: **Stocks in news: Reliance Industries, Bank of Baroda, Power Grid, NATCO Pharma and JSW Infra** — Indian equity markets closed largely unchanged on Friday, August 21, after a volatile trading session. Several companies, including Reliance Industries and Bank of Baroda, reported significant corporate developments. Power Grid Corporation and Jubilant Pharmova also announced key project wins and regulatory approvals. NATCO Pharma and Caplin Point Laboratories received observations from the US FDA after inspections. Mobile manufacturing stocks are expected to gain attention following a new gover... — [Source](https://economictimes.indiatimes.com/markets/stocks/news/stocks-in-news-reliance-industries-bank-of-baroda-power-grid-natco-pharma-and-jsw-infra/articleshow/133444199.cms)
- 2026-08-23 — CNBC-TV18: **Stocks to Watch for August 24: Reliance Industries, NATCO Pharma, Bank of Baroda** — RIL shareholders approved resolutions on Aug 20, 2026. Caplin Point, NATCO Pharma, and Choksi Labs received US FDA Form 483 observations. Mobile & EMS stocks in focus after new manufacturing scheme. — [Source](https://www.cnbctv18.com/photos/market/stocks-to-watch-for-august-24-reliance-industries-natco-pharma-bank-of-baroda-federal-bank-jubilant-pharmova-apollo-micro-systems-19974715.htm)
- 2026-08-22 — BUSINESS: **NATCO Pharma's Visakhapatnam unit gets Form 483 with 4 observations from US FDA** — NATCO Pharma said that the U.S. Food and Drug Administration (US FDA) has issued a Form 483 with four observations post an inspection to the company's manufacturing plant at Visakhapatnam. — [Source](https://www.business-standard.com/markets/capital-market-news/natco-pharma-s-visakhapatnam-unit-gets-form-483-with-4-observations-from-us-fda-126082200318_1.html)
- 2026-08-21 — The Hindu: **Natco Pharma’s Vizag FDF unit gets 4 U.S. FDA observations** — Natco Pharma's Vizag FDF unit receives four FDA observations, but remains confident in addressing them promptly. — [Source](https://www.thehindu.com/business/industry/natco-pharmas-vizag-fdf-unit-gets-4-us-fda-observations/article71374685.ece)
- 2026-08-17 — Economic Times: **Stocks in news: Cochin Shipyard, Voltas, Patanjali Foods, and PhysicsWallah** — Indian stock markets experienced a range-bound week with minor losses for Sensex and Nifty. Analysts are watching four key factors that will influence Dalal Street's action this week. Cochin Shipyard reported a profit decline, while Voltas saw a significant profit surge. Patanjali Foods and Kwality Wall's also posted profit increases. PhysicsWallah narrowed its net loss, and NMDC reported a profit rise. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/stocks-in-news-cochin-shipyard-voltas-patanjali-foods-and-physicswallah/articleshow/133279798.cms)
- 2026-08-17 — The Hindu: **Sensex today | Stock Market LIVE: Stock to buy today: Elgi Equipments (₹609.05)** — Sensex, Nifty, Share Prices Live updates: The  stock Elgi Equipments has been appreciating since February after it found support at ₹420. But after hitting a high of ₹634 on May 29, the price gradually moderated. The rally on Friday indicates that the scrip is likely beginning a new leg of rally now, which can potentially lift the stock to ₹740. — [Source](https://www.thehindubusinessline.com/markets/sensex-nifty50-today-stock-market-live-updates-17th-august-2026/article71354693.ece)
- 2026-08-14 — CNBC-TV18: **Earnings Central: Ashok Leyland, Voltas shine on Friday as Natco Pharma takes a hit** — Ashok Leyland, Voltas and Bharat Dynamics closed the week with strong numbers, while pharma names such as Natco and Alkem faced a tougher session. Management commentary from Solar Industries, Page Industries and Canara Bank added more colour. — [Source](https://www.cnbctv18.com/market/earnings-central-ashok-leyland-voltas-shine-friday-natco-pharma-takes-hit-19969966.htm)
- 2026-08-14 — FREEPRESSJOURNAL.IN: **Natco Pharma Q1 Profit Slumps 57 Per Cent To ₹206.5 Crore On Weak Lenalidomide Sales** — Natco Pharma reported a 57% YoY fall in Q1 FY27 net profit to Rs 206.5 crore as weak lenalidomide sales hurt its international business. Revenue dropped 44.7% to Rs 735.2 crore and EBITDA fell 67.4%. The company also announced an interim dividend of Rs 1.50 per share and approved plans to raise up to Rs 2,000 crore through a QIP. — [Source](https://www.freepressjournal.in/business/natco-pharma-q1-profit-slumps-57-per-cent-to-2065-crore-on-weak-lenalidomide-sales)
- 2026-08-14 — The Hindu: **Natco Pharma Q1 net, revenue slump on lower cancer drug sales** — Natco Pharma's Q1 profit plummets 57% due to declining Lenalidomide sales, resulting in a significant revenue drop. — [Source](https://www.thehindu.com/business/industry/natco-pharma-q1-net-revenue-slump-on-lower-cancer-drug-sales/article71345441.ece)
- 2026-08-14 — The Hindu: **Q1 Results Today Live: BDL, Ashok Leyland, 3M India Q1 PAT rise y-o-y, NATCO Pharma, Alkem Lab PAT decline, NMDC, Voltas, Cochin Shipyard, Physicswallah, PTC Ind, Borosil to announce Q1 results** — Q1 Results Today, 14th August 2026 Live Updates:  Follow Q1FY27 live updates from businessline — [Source](https://www.thehindubusinessline.com/markets/q1-results-today-live-updates-ashok-leylad-nmdc-alkem-lab-bharat-dynamics-voltas-3m-india-cochin-shipyard-physicswallah-cholamandalam-fin-ptc-ind-natco-pharma-tmpv-results-14-august-2026/article71340415.ece)
- 2026-08-14 — MONEYCONTROL: **Taking Stock: Nifty at 24,360, Sensex down 70 pts; media, telecom stocks rally** — Taking Stock,Sensex,Nifty,Indain stock market today,Market today,sensex, sensex today, bse sensex live, stock market, stock market live updates, stock market latest updates, share market, share market updates, nifty50, bse, nse, live market updates, sensex latest updates, latest sensex updates, sensex share price, rupee vs dollar, inr vs usd — [Source](https://www.moneycontrol.com/news/business/markets/taking-stock-nifty-at-24-360-sensex-down-70-pts-media-telecom-stocks-rally-14005699.html)
- 2026-08-14 — CNBC-TV18: **Sensex Today | Stock Market LIVE Updates: Nifty Auto down about 140 points; Tata Motors PV leads loses** — Sensex Today | Stock Market LIVE Updates: We are the half way mark of the day's trade and the markets remain in red. The markets are under pressure, with the Nifty index falling towards the 24,300 mark. The Nifty Bank is also trading on similar ground, falling below the 57,500 mark. Tata Motors PV, Hindalco, Max Health are the top losers. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-sensex-hdfc-bank-nifty-bank-q1-earnings-tata-motors-max-fin-defence-bdl-share-price-liveblog-19969121.htm)
- 2026-08-14 — CNBC-TV18: **Natco Pharma shares fall over 6% after weak Q1 results; Board approves fund raise of up to ₹2,000 crore** — Natco Pharma shares fell sharply after weak Q1 earnings, with profit down 57% to Rs 206.5 crore. The board approved raising up to Rs 2,000 crore. — [Source](https://www.cnbctv18.com/market/natco-pharma-share-price-q1-results-profit-revenue-ebitda-margin-board-approves-fund-raise-up-to-rs-2000-crore-19969617.htm)
- 2026-07-29 — CNBC-TV18: **Eris Lifesciences' Q1 profit jumps 21%, but margins come under pressure** — The drugmaker reported double-digit growth in revenue and profit for the June quarter, even as rising costs squeezed operating margins. — [Source](https://www.cnbctv18.com/market/eris-lifesciences-q1-pat-up-21-pc-shares-gain-2-pc-after-results-19956646.htm)
- 2026-07-20 — The Hindu: **Sensex today | Stock Market Live: Sensex down 500 pts, Nifty holds 24,200 dragged by banking stocks; Brent crude tops $90 amid US-Iran war** — Sensex, Nifty, Share Prices Live Updates: At 10:00, Sensex dropped 576.84 points (-0.74%) to 77,574.61, while Nifty was down 152.00 points (-0.62%) to 24,182.30 — [Source](https://www.thehindubusinessline.com/markets/sensex-nifty50-today-stock-market-live-updates-20th-july-2026/article71241122.ece)
- 2026-07-20 — The Hindu: **Stocks to Watch: JSW Steel, Alembic Pharma, Cipla, Laser Power, 5Paisa, Prestige Estates, NBCC** — [Source](https://www.thehindubusinessline.com/markets/stocks-to-watch-jsw-steel-alembic-pharma-cipla-laser-power-5paisa-prestige-estates-nbcc-india-among-14-stocks-to-be-in-focus-today/article71243684.ece)

## Business profile

**Strategic vision:** Develops, manufactures, and markets pharmaceutical formulations and APIs.

### Business segments
- **Pharmaceutical Formulations:** This segment encompasses the development and sale of finished dosage forms for various therapeutic areas, particularly in niche markets such as oncology.
- **Active Pharmaceutical Ingredients (APIs):** NATCO Pharma develops and manufactures Active Pharmaceutical Ingredients, with expertise in complex chemistry and long synthesis processes, particularly in oncology APIs and specialty products.
- **Crop Health Sciences:** Through this segment, NATCO Pharma provides agrochemicals and biological pest management solutions, addressing insect, disease, and weed management for various crops.

### Competitive strengths
- Vertically integrated structure
- Expertise in complex generics and niche molecules
- In-house research and development capabilities
- State-of-the-art manufacturing units

## Related stocks

- [ABBOTINDIA (Healthcare)](https://faxioms.com/stocks/abbotindia) — +5.50%
- [ACUTAAS (Healthcare)](https://faxioms.com/stocks/acutaas) — +3.86%
- [AJANTPHARM (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +1.61%
- [ALKEM (Healthcare)](https://faxioms.com/stocks/alkem) — +0.14%
- [ANTHEM (Healthcare)](https://faxioms.com/stocks/anthem) — -0.35%

## Freshness and sources

- Data as of: 2026-09-18
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/natcopharm
Markdown representation: https://faxioms.com/stocks/natcopharm?render=md